SG11201501653RA - Methods for the treatment of locally advanced breast cancer - Google Patents

Methods for the treatment of locally advanced breast cancer

Info

Publication number
SG11201501653RA
SG11201501653RA SG11201501653RA SG11201501653RA SG11201501653RA SG 11201501653R A SG11201501653R A SG 11201501653RA SG 11201501653R A SG11201501653R A SG 11201501653RA SG 11201501653R A SG11201501653R A SG 11201501653RA SG 11201501653R A SG11201501653R A SG 11201501653RA
Authority
SG
Singapore
Prior art keywords
treatment
methods
breast cancer
locally advanced
advanced breast
Prior art date
Application number
SG11201501653RA
Other languages
English (en)
Inventor
Anita Gandhi
Jorge Dimartino
Rajesh Chopra
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG11201501653RA publication Critical patent/SG11201501653RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201501653RA 2012-09-10 2013-09-09 Methods for the treatment of locally advanced breast cancer SG11201501653RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699170P 2012-09-10 2012-09-10
PCT/US2013/058744 WO2014039960A1 (en) 2012-09-10 2013-09-09 Methods for the treatment of locally advanced breast cancer

Publications (1)

Publication Number Publication Date
SG11201501653RA true SG11201501653RA (en) 2015-04-29

Family

ID=49170950

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501653RA SG11201501653RA (en) 2012-09-10 2013-09-09 Methods for the treatment of locally advanced breast cancer

Country Status (15)

Country Link
US (1) US9694015B2 (enrdf_load_stackoverflow)
EP (1) EP2892537A1 (enrdf_load_stackoverflow)
JP (1) JP6306592B2 (enrdf_load_stackoverflow)
KR (1) KR20150054962A (enrdf_load_stackoverflow)
CN (1) CN104797256A (enrdf_load_stackoverflow)
AU (1) AU2013312188A1 (enrdf_load_stackoverflow)
BR (1) BR112015005243A2 (enrdf_load_stackoverflow)
CA (1) CA2884103A1 (enrdf_load_stackoverflow)
EA (1) EA201590535A1 (enrdf_load_stackoverflow)
IL (1) IL237558A0 (enrdf_load_stackoverflow)
MX (1) MX2015003114A (enrdf_load_stackoverflow)
NI (1) NI201500032A (enrdf_load_stackoverflow)
PH (1) PH12015500513A1 (enrdf_load_stackoverflow)
SG (1) SG11201501653RA (enrdf_load_stackoverflow)
WO (1) WO2014039960A1 (enrdf_load_stackoverflow)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104876908A (zh) 2006-09-26 2015-09-02 细胞基因公司 作为抗肿瘤剂的5-取代的喹唑酮衍生物
KR101812356B1 (ko) 2010-02-11 2017-12-26 셀진 코포레이션 아릴메톡시 이소인돌린 유도체 및 그를 포함하는 조성물 및 그의 사용 방법
CA3109687A1 (en) 2011-03-11 2012-09-20 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US9682952B2 (en) 2012-09-04 2017-06-20 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP3116872A4 (en) * 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US9687485B2 (en) 2014-06-13 2017-06-27 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
EA037738B1 (ru) 2014-08-07 2021-05-17 Калитера Байосайенсиз, Инк. Кристаллические формы ингибиторов глутаминазы
BR112017021312A2 (pt) 2015-04-06 2018-06-26 Calithera Biosciences Inc tratamento de câncer de pulmão com inibidores de glutaminase
US10338077B2 (en) * 2015-06-02 2019-07-02 Celgene Corporation Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
ES2880482T3 (es) 2016-01-11 2021-11-24 Epicentrx Inc Composiciones y métodos para la administración intravenosa de 2-bromo-1-(3,3-dinitroazetidin-1-il)etanona
CN110139649A (zh) 2016-08-25 2019-08-16 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
RU2655625C1 (ru) * 2017-02-14 2018-05-29 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" Способ лечения рака молочной железы у кошки
IL271777B2 (en) * 2017-07-07 2024-09-01 Epicentrx Inc Compositions for parenteral administration of therapeutic agents
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
PT3820573T (pt) * 2018-07-10 2023-10-30 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona e seu uso no tratamento de doenças dependentes do dedo de zinco 2 da família ikaros (ikzf2)
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN112654619B (zh) 2018-09-07 2022-08-30 南京明德新药研发有限公司 三环并呋喃取代哌啶二酮类化合物
EP4043455A4 (en) * 2019-09-12 2023-09-20 Medshine Discovery Inc. BICYCLIC COMPOUND THAT ACTS AS A REGULATOR OF CRBN PROTEIN
US20230158152A1 (en) * 2020-03-17 2023-05-25 Medshine Discovery Inc. Proteolysis regulator and method for using same
KR20230007384A (ko) * 2020-04-30 2023-01-12 브리스톨-마이어스 스큅 컴퍼니 치료 방법
MX2022015891A (es) * 2020-06-25 2023-01-24 Celgene Corp Metodos para tratar cancer con terapias combinadas.
CN115724775B (zh) * 2022-11-22 2024-11-29 天津大学 一种贝利司他药物共晶及其制备方法和应用
WO2025024823A1 (en) * 2023-07-27 2025-01-30 Plexium, Inc. Salts and solid forms of compounds that modulate ikzf2

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
PT1353672E (pt) 2000-11-30 2008-01-11 Childrens Medical Center Síntese da 4-amino talidomida enantiómeros
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2003234626B2 (en) * 2002-05-17 2006-03-09 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
CN104876908A (zh) * 2006-09-26 2015-09-02 细胞基因公司 作为抗肿瘤剂的5-取代的喹唑酮衍生物
KR101812356B1 (ko) 2010-02-11 2017-12-26 셀진 코포레이션 아릴메톡시 이소인돌린 유도체 및 그를 포함하는 조성물 및 그의 사용 방법
CA2805774A1 (en) * 2010-07-19 2012-01-26 Charles Bradley Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
CA2811015A1 (en) * 2010-09-15 2012-03-22 Almac Diagnostics Limited Molecular diagnostic test for cancer
CA3109687A1 (en) 2011-03-11 2012-09-20 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
JP6118273B2 (ja) 2011-03-11 2017-04-19 セルジーン コーポレイション 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用
US9365640B2 (en) 2011-04-29 2016-06-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2014004990A2 (en) * 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
ES2881220T3 (es) 2012-08-09 2021-11-29 Celgene Corp Métodos de tratamiento del cáncer usando 3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona

Also Published As

Publication number Publication date
US9694015B2 (en) 2017-07-04
CA2884103A1 (en) 2014-03-13
CN104797256A (zh) 2015-07-22
IL237558A0 (en) 2015-04-30
MX2015003114A (es) 2015-07-06
EA201590535A1 (ru) 2015-07-30
EP2892537A1 (en) 2015-07-15
US20150224104A1 (en) 2015-08-13
NI201500032A (es) 2015-09-21
JP2015527404A (ja) 2015-09-17
AU2013312188A1 (en) 2015-03-26
BR112015005243A2 (pt) 2017-07-04
JP6306592B2 (ja) 2018-04-04
PH12015500513A1 (en) 2015-04-27
KR20150054962A (ko) 2015-05-20
WO2014039960A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL237558A0 (en) Methods for treating locally advanced breast cancer
IL267242B (en) Cancer treatment
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
PH12014500248A1 (en) Treatment of breast cancer
GB201117956D0 (en) Phytocannabinoids for use in the treatment of breast cancer
IL238116B (en) A process for preparing compounds for use in the treatment of cancer
EP2903644A4 (en) TREATMENT OF CANCER
IL254964A0 (en) A method for treating breast cancer
PL2892535T3 (pl) Sposób leczenia adjuwantowego raka
GB201217892D0 (en) Treatment of cancer
EP2849786A4 (en) METHOD FOR THE TREATMENT OF GASCULAR CANCER
DK2872176T3 (en) Cancer treatment
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
GB201222563D0 (en) Cancer treatment
GB201208296D0 (en) Treatment of cancer